Autonomic Testing

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Oscar may delegate utilization management decisions of certain services to third-party delegates, who may develop and adopt their own clinical criteria.

The clinical guidelines are applicable to all commercial plans. Services are subject to the terms, conditions, limitations of a member’s plan contracts, state laws, and federal laws. Please reference the member’s plan contracts (e.g., Certificate/Evidence of Coverage, Summary/Schedule of Benefits) or contact Oscar at 855-672-2755 to confirm coverage and benefit conditions.

Summary

The autonomic nervous system (ANS) regulates parts of the body that are not consciously controlled, such as blood pressure, heart rate, body temperature, and many others. It includes sympathetic nerves (e.g., the “fight-or-flight” system) and parasympathetic nerves (e.g., the “rest-and-digest” system). Certain diseases, injuries, and medications can impair the ANS, resulting in “autonomic dysfunction”. Because the autonomic nervous system is widespread throughout the body, clinical manifestations can vary depending on the underlying process. Some signs of dysfunction include impaired blood pressure and heart autoregulation, abnormal sweat production, heat or cold intolerance, digestive problems, erectile dysfunction, or problems with urination and bowel movements. There are a number of tests to evaluate the autonomic nervous system. These are generally performed by applying a stimulus to the affected organ system and measuring for the appropriate autonomic response (or lack thereof). This guideline covers the clinical criteria and exclusions for autonomic testing.

This guideline does not cover the clinical criteria, exclusions, or benefit details for testing of the somatosensory nervous system, which is also part of the peripheral nervous system, but controls musculature, sensory input, and other voluntary systems.
Definitions

"Autonomic Nervous System (ANS)" is a division of the peripheral nervous system (i.e., nerves and ganglia outside the brain and spinal cord). It controls involuntary actions such as, but not limited to, blood pressure, urination/defecation, sexual function, digestion, and glandular secretion (sweat, saliva, tears, etc.).

"Dysautonomia," or autonomic dysfunction, occurs when the ANS is damaged or impaired by some disease, injury, or medication.

1. Signs of dysautonomia include, but are not limited to:
   - Orthostatic hypotension
   - Urinary incontinence or retention
   - Bradycardia or tachycardia
   - Changes in vision
   - Dizziness
   - Syncope
   - Digestive issues

2. Causes of dysautonomia include, but are not limited to:
   - Parkinson’s disease and associated parkinsonian syndromes
   - Diabetes mellitus and other neuropathies
   - Surgical or iatrogenic injury
   - Autoimmune diseases such as SLE or Sjogren’s disease
   - HIV and AIDS
   - Multiple sclerosis
   - Toxicity from medications and drugs
   - Amyloidosis

3. The diagnosis of dysautonomia relies on three autonomic functions:
   - Cardiovagal, which is the parasympathetic response in heart rate to breathing and valsalva maneuvers (e.g. holding your breath and bearing down);
   - Vasomotor or adrenergic, which refers to the sympathetic-mediated constriction of blood vessels to increase blood pressure;
   - Sudomotor, which is sweat production in response to sympathetic stimuli

"Somatosensory Nervous System" is also a division of the peripheral nervous system. It controls voluntary actions such as muscle use, as well as sensory input and reflexes. Testing of the somatosensory nervous system differs from the ANS and is usually performed through various nerve conduction studies.
It also differs from testing of the central nervous system and associated nerves, which is often performed through evoked potential or evoked response testing.

“Sympathetic” nerves are a part of the ANS responsible for the “fight-or-flight” response, which diverts blood away from nonessential organs, increases heart rate and contractility, and dilates the pupils, among other functions. It is counteracted by the parasympathetic system.

“Parasympathetic” nerves are part of the ANS responsible for the “rest-and-digest” response, which activates digestions and peristalsis while decreasing cardiac and lung function, among other functions.

“Sudomotor” refers to a branch of the sympathetic nervous system that controls sweat glands. The sudomotor system is a frequent surrogate for testing autonomic dysfunction as it is easily stimulated and accessible for measurement of response (i.e. sweat production). The various tests for sudomotor function are defined below.

“QSART (Qualitative Sudomotor Axon Reflex Test)” is a test used to diagnose autonomic dysfunction by evaluating the postganglionic sudomotor nerves. To perform this test, acetylcholine (which stimulates sweat excretion) is released into the skin, and the sweat response is recorded.

“QDIRT (Quantitative Direct and Indirect Testing of Sudomotor Function)” is similar to QSART, but also adds temporal and volumetric data on the sweat production. QDIRT is more variable than QSART and normative values have yet to be clearly established.

“QPART” (Quantitative Pilomotor Axon Reflex Test) is a test of piloerection (e.g. “goose bumps”), which is an alternative expression of autonomic function. The clinical role of QPART has not yet been established in the literature.

“TST” (Thermoregulatory Sweat Test) tests sudomotor function from the pre- and post-ganglionic nerves. The test is conducted by applying an indicator dye over the skin surface, and then placing the patient in a heated enclosure to increase the core body temperature. The indicator will change color in areas where sweat is produced and remain unchanged in areas of dysfunction.

“Silastic Sweat Imprinting” is a technique like QSART, however the sweat drops are recorded as imprints in a silastic material to quantify the response.
“SSR” (Sympathetic Skin Response) is a test to measure changes in skin electrical potential in response to an arousing stimulus. SSR is difficult to reproduce accurately and may lack the sensitivity and specificity for broad clinical application.

“Tilt-Table Test” is used to assess adrenergic sympathetic activity (e.g. the vasomotor response). Patients are positioned supine on a table and allowed to acclimate. The table is then tilted to an upright position to mimic standing for 20-45 minutes. Blood pressure, heart rate, and sometimes EKG tracings are recorded for each position at set time points. In a normal physiologic response, the blood vessels should constrict to maintain cerebral perfusion. In autonomic dysfunction, there is a failure of the body’s response to adjust for blood pressure and heart rate, resulting in multiple symptoms including but not limited to dizziness and potential syncope.

“Syncope” is the temporary loss of consciousness and muscle tone due to inadequate brain perfusion. It is typically self-limited and resolves quickly without significant intervention, depending on the underlying cause.

Clinical Indications and Coverage

Tilt-Table Testing

Tilt-table testing, alone or with provocative agents (e.g. isoproterenol), is considered medically necessary and covered when ALL of the following criteria are met:

1. The patient has a history of syncope or recurrent syncopal episodes, with further testing indicated for at least ONE of the following:
   a. Suspected carotid sinus hypersensitivity; or
   b. Evaluation is needed for a patient returning to high-risk work (i.e. commercial driving, operating machinery, etc.) or a leisure activity that may place the patient at risk; or
   c. Neurally mediated syncope is suspected, including:
      i. Vasovagal syncope, except when this is the first episode of suspected vasovagal syncope; or
      ii. Carotid sinus dysfunction; or
      iii. Situational syncope.
   d. Postural orthostatic hypotension syndrome (POTS); or
   e. For other conditions where the results of the tilt-table test would change medical management (i.e. medications or further workup would be indicated).

2. Cardiac causes of syncope have been excluded via the appropriate non-invasive tests and workup (e.g. history and physical exam, EKG, stress test, and/or cardiac echocardiogram); and
3. Comorbid conditions that may have contributed have been diagnosed, adequately treated, and/or ruled out (e.g. hypovolemia, bleeding, shock, seizures, infections, anemia, etc); and
4. Medications that may contribute to autonomic dysfunction and/or syncopal episodes have been adjusted or discontinued; and
5. There are NOT contraindications to tilt-table testing, including but not limited to:
   a. Critical valvular stenosis
   b. Left ventricular outflow tract obstruction
   c. Severe proximal cerebral artery stenosis or coronary artery disease
6. Testing is ordered ONCE when used to exclude specific autonomic diseases, or no more than once annually for patients who have already been diagnosed with autonomic dysfunction and meet criteria for a repeat test.

Sudomotor Testing
Sudomotor testing is considered medically necessary and covered when ALL of the following criteria are met:
1. Testing is ordered for QSART, silastic sweat imprint, or TST; and
2. The testing is conducted by physicians with the appropriate expertise and training to perform and interpret the tests results; and
3. Testing is ordered ONCE when used to exclude specific autonomic diseases, or no more than once annually for patients who have already been diagnosed with autonomic dysfunction and meet criteria for a repeat test; and
4. Testing is ordered for one of the following:
   a. To diagnose an appropriate condition, specified as any one or more of the following:
      i. Peripheral neuropathies:
         ● Amyloid neuropathy; or
         ● Diabetic autonomic neuropathy; or
         ● Distal small fiber neuropathy; or
         ● Idiopathic neuropathy.
      ii. Multiple systems atrophy; or
      iii. Sjogren’s disease; or
      iv. Pure autonomic failure; or
      v. Postural orthostatic hypotension syndrome (POTS) or postural tachycardia syndrome; or
      vi. Reflex sympathetic dystrophy or causalgia; or
      vii. Recurrent syncope without a known cause despite appropriate workup.
   b. To evaluate any one or more of the following:
i. The severity and/or distribution of a previous diagnosed autonomic neuropathy that is progressing; or

ii. The change in severity, distribution, or type of autonomic dysfunction in a patient who has previously exhibited signs of autonomic failure but does not yet have a diagnosis; or

iii. The response to treatment in a patient with autonomic dysfunction who had recent changes in symptoms and clinical exam findings; or

iv. To evaluate inadequate response to beta blocker therapy in vasodepressor syncope.

**Coverage Exclusions**

**Tilt-Table Testing**

Tilt-table testing is considered investigational and/or experimental, and thus NOT medically necessary, in the following situations:

a. Any indication not meeting the above criteria; or

b. Solely for following the effectiveness or response to treatment for syncope; or

c. To evaluate dizziness, near syncope, or vertigo; or

d. To evaluate post-concussive syndrome; or

e. To evaluate chronic fatigue syndrome; or

f. Suspected vasovagal syncope with a single episode or when the diagnosis is established through history and physical exam; or

g. To differentiate convulsive syncope from epilepsy in a patient with recurrent loss of consciousness associated with tonic-clonic movements; or

h. To evaluate for unexplained recurrent falls when there is no sign of cardiovagal instability; or

i. To evaluate patients with recurrent transient ischemic attacks (TIAs).

**Sudomotor Testing**

Sudomotor testing is considered investigational and/or experimental, and thus NOT medically necessary, in the following situations:

1. Any condition or test not meeting the specific criteria above, such as chronic fatigue syndrome, myalgia, encephalomyelitis, Raynaud phenomenon, traumatic brain injury or predicting foot ulcers; or

2. Screening for patients without signs or symptoms of autonomic dysfunction, regardless of their current diagnoses; or

3. Testing solely performed to monitor disease intensity or treatment efficacy, unless otherwise specified above; or
4. Testing when the results will not impact clinical management; or
5. Clearly diagnosed somatosensory neuropathies that have not changed in severity and/or distribution of symptoms, including but not limited to the demyelinating neuropathies (e.g. guillain-barre, CIDP, etc); or
6. The following sudomotor testing methods are NOT indicated for any condition as there is insufficient evidence to support clinical effectiveness in the existing literature:
   a. SSR; or
   b. QDIRT; or
   c. QPART; or
   d. Any ambulatory and/or automatic measuring device for autonomic function, including but not limited to:
      i. Sudoscan; or
      ii. ANSAR and Medeia QANS/AHRV System; or
      iii. Zephyr Bioharness or Biopatch.

Applicable Billing Codes

<table>
<thead>
<tr>
<th>CPT/HCPCS Codes covered if criteria are met:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Code</td>
</tr>
<tr>
<td>------</td>
</tr>
<tr>
<td>95921</td>
</tr>
<tr>
<td>95922</td>
</tr>
<tr>
<td>95923</td>
</tr>
<tr>
<td>95924</td>
</tr>
<tr>
<td>95943</td>
</tr>
</tbody>
</table>
rate variability concurrent with time-frequency analysis of continuous respiratory activity, with mean heart rate and blood pressure measures, during rest, paced (deep) breathing, Valsalva maneuvers, and head-up postural change

**ICD-10 codes covered if criteria are met:**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>E08.42; E09.42</td>
<td>Polyneuropathy in diabetes</td>
</tr>
<tr>
<td>E10.40 - E10.49; E11.40 - E11.49; E13.40 - E13.49</td>
<td>Diabetes with neurological manifestations</td>
</tr>
<tr>
<td>E85.1</td>
<td>Amyloid heredofamilial amyloidosis [amyloid polyneuropathy]</td>
</tr>
<tr>
<td>G56.40 - G56.43</td>
<td></td>
</tr>
<tr>
<td>G57.70 - G57.73</td>
<td>Causalgia</td>
</tr>
<tr>
<td>G60.3</td>
<td>Idiopathic progressive neuropathy</td>
</tr>
<tr>
<td>G60.8</td>
<td>Other hereditary and idiopathic neuropathies [distal small fiber neuropathy]</td>
</tr>
<tr>
<td>G63</td>
<td>Polyneuropathy in diseases classified elsewhere [when coded with E85.1]</td>
</tr>
<tr>
<td>G90.0 - G90.9</td>
<td>Disorders of autonomic nervous system</td>
</tr>
<tr>
<td>G90.01 - G90.09</td>
<td>Idiopathic peripheral autonomic neuropathy</td>
</tr>
<tr>
<td>G90.3</td>
<td>Multi-system degeneration of the autonomic nervous system</td>
</tr>
<tr>
<td>G90.50 - G90.59</td>
<td>Complex regional pain syndrome I (CRPS I) [Reflex sympathetic dystrophy]</td>
</tr>
<tr>
<td>G90.8</td>
<td>Other disorders of autonomic nervous system [when used for pure autonomic failure]</td>
</tr>
<tr>
<td>G99.0</td>
<td>Autonomic neuropathy in diseases classified elsewhere [when coded with E85.0 - E85.9]</td>
</tr>
<tr>
<td>M35.00 - M35.09</td>
<td>Sicca syndrome [Sjögren]</td>
</tr>
<tr>
<td>R00.0</td>
<td>Tachycardia, unspecified [postural tachycardia syndrome]</td>
</tr>
</tbody>
</table>
Syncope and collapse

ICD-10 codes not covered:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>F07.81</td>
<td>Postconcussional syndrome</td>
</tr>
<tr>
<td>G04.00 - G04.02</td>
<td>Acute disseminated encephalitis and encephalomyelitis (ADEM)</td>
</tr>
<tr>
<td>G04.81; G04.90</td>
<td>Other and unspecified encephalitis and encephalomyelitis</td>
</tr>
<tr>
<td>G05.3</td>
<td>Encephalitis and encephalomyelitis in diseases classified elsewhere</td>
</tr>
<tr>
<td>G45.8 - G45.9</td>
<td>Transient cerebral ischemic attacks and related syndromes</td>
</tr>
<tr>
<td>I73.00 - I73.01</td>
<td>Raynaud's syndrome</td>
</tr>
<tr>
<td>M79.1</td>
<td>Myalgia</td>
</tr>
<tr>
<td>R53.82</td>
<td>Chronic fatigue, unspecified</td>
</tr>
<tr>
<td>S06.2x0A - S06.309S</td>
<td>Diffuse traumatic brain injury</td>
</tr>
</tbody>
</table>

References


34. Humm AM, Mathias CJ. Unexplained syncope—is screening for carotid sinus hypersensitivity indicated in all patients aged >40 years? J Neurol Neurosurg Psychiatry. 2006;77(11):1267-1270.


Clinical Guideline Revision / History Information

<table>
<thead>
<tr>
<th>Original: Review/Revise Dates</th>
<th>Approval Signature/ Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original Date:</td>
<td>8/21/2017</td>
</tr>
<tr>
<td>Reviewed/Revised:</td>
<td>1/18/2018</td>
</tr>
<tr>
<td>Signed:</td>
<td>Sean Martin, MD, Medical Director</td>
</tr>
</tbody>
</table>